Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01824836 · ClinicalTrials.gov registry record · NA
A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)
A NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 1,046
- Enrollment target
- 2
- Study locations
NCT01824836: Active NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, sponsored by ECOG-ACRIN Cancer Research Group.
NCT01824836 is a NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1,046 participants, above the 284-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (268% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01824836, a NA study of Stage II Breast Cancer and Stage IIIA Breast Cancer, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,046 participants
- Enrollment target
- 2
- Study locations
Study Summary
E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS). Women with stage I-III breast cancer who are prescribed the aromatase inhibitor anastrozole as treatment may join.
Primary Outcome
Patients were classified into two groups based on whether or not they discontinued treatment due to MSS within 12 months. The 10 SNPs evaluated include ESR1 (rs2234693, rs2347868, rs9340835), CYP19A1 (rs1062033, rs4646), TCL1A (rs11849538, rs2369049, rs7158782, rs7159713), and HTR2A (rs2296972). The associations between SNPs and discontinuation of treatment due to AIMSS are presented by odds ratios (ORs). An OR of 1 suggests no association, while an OR \> 1 indicates a greater chance of treatme
Conditions Studied
Interventions
- DRUG anastrozole
Study Locations (2)
Massachusetts
- Eastern Cooperative Oncology Group - Boston
New Jersey
- Veterans Adminstration New Jersey Health Care System - East Orange
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,046 participants |
| Start Date | 2013-06-11 |
| Est. Completion | 2026-12 |
| Phase | NA |
What the registry record for NCT01824836 still lists
NCT01824836 is an interventional study that assigns participants to a tested intervention. Its 1,046 participants enrollment target places it among the larger protocols in the corpus, above the 284-participant average among 30 other Stage II Breast Cancer trials with a reported enrollment target (268% higher).
The record links to 10 conditions, with Stage II Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which anastrozole is the first listed.
NCT01824836 reports a single indexed study location in Massachusetts, New Jersey.
Frequently Asked Questions
What is clinical trial NCT01824836 about?
NCT01824836 is a clinical study titled "A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)". E1Z11 is a study to determine whether certain genetic information can predict which breast cancer patients will discontinue treatment with aromatase inhibitors (AIs) due to the development of musculoskeletal symptoms (MSS). Women with stage I-III breast cancer who are prescribed the aromatase inhibi...
What is the current status of trial NCT01824836?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,046 participants. The study started on 2013-06-11. Estimated completion is 2026-12.
What conditions does trial NCT01824836 study?
This clinical trial studies the following conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Recurrent Breast Cancer.
What interventions are being tested in trial NCT01824836?
The interventions under investigation include: anastrozole (DRUG).
Who is sponsoring clinical trial NCT01824836?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01824836 being conducted?
This trial has 2 study locations across Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01824836's enrollment target sits among peer trials
1,046 4th of 30 higher than 27 of 30 other Stage II Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage II Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
RECRUITING · NA
-
TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
RECRUITING · NA
-
Improving Exercise Capacity With a Tailored Physical Activity Intervention
RECRUITING · NA
-
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
ACTIVE NOT RECRUITING · NA
-
Researching the Effect of Exercise on Cancer
ACTIVE NOT RECRUITING · NA
-
Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI